Literature DB >> 10903228

Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma.

N Krug1, W W Cruikshank, T Tschernig, V J Erpenbeck, K Balke, J M Hohlfeld, D M Center, H Fabel.   

Abstract

IL-16 has been shown to be one of the earliest CD4(+) cell chemoattractants present in BAL 4-6 h after antigen challenge but little is known about its persistence and biological activity after 6 h. We determined the concentration of IL-16 using ELISA and the T-cell chemoattractant activity using a modified Boyden chamber assay in unconcentrated BAL fluid from 13 patients with mild asthma and 9 nonatopic control subjects at baseline and 24 h after segmental allergen or saline challenge. Furthermore, the percentage of IL-16-producing T cells was determined in the different samples of BAL fluid using a flow cytometric intracellular cytokine assay. Although no substantial levels of IL-16 protein were detectable in BAL fluid from control subjects and patients with asthma at baseline and after saline challenge, IL-16 concentrations were significantly elevated in patients with asthma after allergen challenge (median, 97 pg/ml; range, 38-362 pg/ml; p < 0.01). Furthermore, there was an increased T-cell chemoattractant activity after allergen challenge in patients with asthma (p < 0.01), which could be blocked by preincubation with anti-IL-16 antibodies and which correlated significantly with the IL-16 protein levels (R = 0.90, p < 0.01) and with the level of Fas ligand expression on BAL CD4(+) cells (R = 0. 80, p < 0.05). A high percentage (mean 70-90%) of CD4(+) and CD8(+) cells stained positively for IL-16 in both patients with asthma and control subjects without differences after allergen or saline challenge. These data demonstrate that the increased chemotactic activity for T cells in patients with asthma is mainly attributable to IL-16. Although T cells by themselves are able to produce IL-16, other cells, such as epithelial cells, have to be considered as further sources for this cytokine in patients with asthma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903228     DOI: 10.1164/ajrccm.162.1.9908055

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  5 in total

Review 1.  Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies.

Authors:  Manuel A R Ferreira
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

2.  Human mid-gestation amniotic fluid contains interleukin-16 bioactivity.

Authors:  Catherine A Thornton; Judith A Holloway; Janis K Shute; John W Holloway; Norma D Diaper; John O Warner
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

3.  Integrative omics approach identifies interleukin-16 as a biomarker of emphysema.

Authors:  Russell P Bowler; Timothy M Bahr; Grant Hughes; Sharon Lutz; Yu-Il Kim; Christopher D Coldren; Nichole Reisdorph; Katerina J Kechris
Journal:  OMICS       Date:  2013-10-19

4.  Large-scale genome-wide association studies and meta-analyses of longitudinal change in adult lung function.

Authors:  Wenbo Tang; Matthew Kowgier; Daan W Loth; María Soler Artigas; Bonnie R Joubert; Emily Hodge; Sina A Gharib; Albert V Smith; Ingo Ruczinski; Vilmundur Gudnason; Rasika A Mathias; Tamara B Harris; Nadia N Hansel; Lenore J Launer; Kathleen C Barnes; Joyanna G Hansen; Eva Albrecht; Melinda C Aldrich; Michael Allerhand; R Graham Barr; Guy G Brusselle; David J Couper; Ivan Curjuric; Gail Davies; Ian J Deary; Josée Dupuis; Tove Fall; Millennia Foy; Nora Franceschini; Wei Gao; Sven Gläser; Xiangjun Gu; Dana B Hancock; Joachim Heinrich; Albert Hofman; Medea Imboden; Erik Ingelsson; Alan James; Stefan Karrasch; Beate Koch; Stephen B Kritchevsky; Ashish Kumar; Lies Lahousse; Guo Li; Lars Lind; Cecilia Lindgren; Yongmei Liu; Kurt Lohman; Thomas Lumley; Wendy L McArdle; Bernd Meibohm; Andrew P Morris; Alanna C Morrison; Bill Musk; Kari E North; Lyle J Palmer; Nicole M Probst-Hensch; Bruce M Psaty; Fernando Rivadeneira; Jerome I Rotter; Holger Schulz; Lewis J Smith; Akshay Sood; John M Starr; David P Strachan; Alexander Teumer; André G Uitterlinden; Henry Völzke; Arend Voorman; Louise V Wain; Martin T Wells; Jemma B Wilk; O Dale Williams; Susan R Heckbert; Bruno H Stricker; Stephanie J London; Myriam Fornage; Martin D Tobin; George T O'Connor; Ian P Hall; Patricia A Cassano
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

Review 5.  Characteristics of tertiary lymphoid structures in primary cancers.

Authors:  Jérémy Goc; Wolf-Herman Fridman; Catherine Sautès-Fridman; Marie-Caroline Dieu-Nosjean
Journal:  Oncoimmunology       Date:  2013-10-22       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.